A Study to Evaluate Self-esteem and Relationships in Males With Erectile Dysfuntion
NCT ID: NCT00648596
Last Updated: 2021-02-01
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
780 participants
INTERVENTIONAL
2003-05-31
2004-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Multicenter, Randomized, Parallel Group, Double-Blind, Placebo Controlled, Flexible Dose Escalation Study To Evaluate Sexual And Relationship Satisfaction In The Female Partner Of Men With Erectile Dysfunction Treated With Sildenafil Citrate
NCT00644631
Assessment of Efficacy of Vardenafil, Influence on Self-esteem and Self-confidence in Subjects With Erectile Dysfunction
NCT00661596
Study to Evaluate Viagra's Ability to Provide a Better Sexual Experience Through Quality Erections and Satisfaction
NCT00245258
Study Of Men With Mild To Moderate Erectile Dysfunction To Evaluate The Efficacy Of Viagra 8 Hours Post-Dose
NCT00143260
Treatment of Erectile Dysfunction II
NCT01037218
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Arm 2
placebo
placebo tablet by mouth 1 hour before sexual activity for 12 weeks
Arm 1
sildenafil
sildenafil 50 mg tablet by mouth 1 hour before sexual activity for 12 weeks; the dose could be increased to 100 mg or decreased to 25 mg.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
sildenafil
sildenafil 50 mg tablet by mouth 1 hour before sexual activity for 12 weeks; the dose could be increased to 100 mg or decreased to 25 mg.
placebo
placebo tablet by mouth 1 hour before sexual activity for 12 weeks
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Subjects with resting sitting hypotension (BP \< 90/50mmHg) or hypertension (BP \> 170/110mmHg)
* Subjects with significant cardiovascular disease, including cardiac failure, myocardial infarction, unstable angina, stroke or transient ischaemic attack (TIA), symptomatic or clinically significant cardiac arrhythmias in the last 3 months
* Patients on nitrates.
18 Years
MALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pfizer CT.gov Call Center
Role: STUDY_DIRECTOR
Pfizer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Pfizer Investigational Site
Oulu, , Finland
Pfizer Investigational Site
Tampere, , Finland
Pfizer Investigational Site
Turku, , Finland
Pfizer Investigational Site
Clermont-Ferrand, , France
Pfizer Investigational Site
LE Kremlin Bicentre, , France
Pfizer Investigational Site
Lyon, , France
Pfizer Investigational Site
Marseille, , France
Pfizer Investigational Site
Neuilly-sur-Seine, , France
Pfizer Investigational Site
Nice, , France
Pfizer Investigational Site
Nîmes, , France
Pfizer Investigational Site
Toulouse, , France
Pfizer Investigational Site
Bari, , Italy
Pfizer Investigational Site
Catania, , Italy
Pfizer Investigational Site
Gallarate (VA), , Italy
Pfizer Investigational Site
Modena, , Italy
Pfizer Investigational Site
Padua, , Italy
Pfizer Investigational Site
Roma, , Italy
Pfizer Investigational Site
Siena, , Italy
Pfizer Investigational Site
Torino, , Italy
Pfizer Investigational Site
Krakow, , Poland
Pfizer Investigational Site
Lodz, , Poland
Pfizer Investigational Site
Lublin, , Poland
Pfizer Investigational Site
Olsztyn, , Poland
Pfizer Investigational Site
Szczecin, , Poland
Pfizer Investigational Site
Warsaw, , Poland
Pfizer Investigational Site
Barnaul, , Russia
Pfizer Investigational Site
Moscow, , Russia
Pfizer Investigational Site
Moscow, , Russia
Pfizer Investigational Site
Moscow, , Russia
Pfizer Investigational Site
Moscow, , Russia
Pfizer Investigational Site
Moscow, , Russia
Pfizer Investigational Site
Moscow, , Russia
Pfizer Investigational Site
Moscow, , Russia
Pfizer Investigational Site
Moscow, , Russia
Pfizer Investigational Site
Nizhny Novgorod, , Russia
Pfizer Investigational Site
Novosibirsk, , Russia
Pfizer Investigational Site
Novosibirsk, , Russia
Pfizer Investigational Site
Rostov-on-Don, , Russia
Pfizer Investigational Site
Saint Petersburg, , Russia
Pfizer Investigational Site
Saint Petersburg, , Russia
Pfizer Investigational Site
Saint Petersburg, , Russia
Pfizer Investigational Site
Yekaterinburg, , Russia
Pfizer Investigational Site
San Juan, Alicante, Spain
Pfizer Investigational Site
Barakaldo, Vizcaya, Spain
Pfizer Investigational Site
Barcelona, , Spain
Pfizer Investigational Site
Madrid, , Spain
Pfizer Investigational Site
Madrid, , Spain
Pfizer Investigational Site
Madrid, , Spain
Pfizer Investigational Site
Valencia, , Spain
Pfizer Investigational Site
Valencia, , Spain
Pfizer Investigational Site
Zaragoza, , Spain
Pfizer Investigational Site
Karlshamn, , Sweden
Pfizer Investigational Site
Malmo, , Sweden
Pfizer Investigational Site
Skövde, , Sweden
Pfizer Investigational Site
Stockholm, , Sweden
Pfizer Investigational Site
Värnamo, , Sweden
Pfizer Investigational Site
Västervik, , Sweden
Pfizer Investigational Site
Bodelwyddan, Denbighshire, United Kingdom
Pfizer Investigational Site
South Yorkshire, DN1 2ET, United Kingdom
Pfizer Investigational Site
Belmont, Durham, United Kingdom
Pfizer Investigational Site
Blackpool, Lancashire, United Kingdom
Pfizer Investigational Site
Urmston, Manchester, United Kingdom
Pfizer Investigational Site
Ashford, Middlesex, United Kingdom
Pfizer Investigational Site
Nr Lichfield, Staffordshire, United Kingdom
Pfizer Investigational Site
Addlestone, Surrey, United Kingdom
Pfizer Investigational Site
Taunton, TA1 5DA, United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
To obtain contact information for a study center near you, click here.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
A1481161
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.